LEXINGTON, Massachusetts, March 1, 2017 /PRNewswire/ --
Shire plc (LSE: SHP, NASDAQ: SHPG) announces that Jeff Poulton, Chief Financial Officer, will participate at the Cowen 37th Annual Healthcare Conference in Boston, MA on Monday, March 6, 2017 at 1:20 p.m. ET (18:20 GMT).
A live audio webcast will be available on the Presentations and Webcasts section of Shire's Investor website at http://investors.shire.com/presentations-and-webcasts/. Subsequently, a replay of the webcast will be available on this same website for approximately 90 days.
NOTES TO EDITORS
About Shire
Shire is the leading global biotechnology company focused on serving people with rare diseases and other highly specialized conditions. We strive to develop best-in-class products, many of which are available in more than 100 countries, across core therapeutic areas including Hematology, Immunology, Neuroscience, Ophthalmics, Lysosomal Storage Disorders, Gastrointestinal / Internal Medicine / Endocrine and Hereditary Angioedema; and a growing franchise in Oncology.
Our employees come to work every day with a shared mission: to develop and deliver breakthrough therapies for the hundreds of millions of people in the world affected by rare diseases and other high-need conditions, and who lack effective therapies to live their lives to the fullest.
http://www.shire.com
For further information please contact: Investor Relations Ian Karp [email protected] +1-781-482-9018
Robert Coates [email protected] +44-1256-894874
SOURCE Shire plc
Advertisement
Shire plc (LSE: SHP, NASDAQ: SHPG) announces that Jeff Poulton, Chief Financial Officer, will participate at the Cowen 37th Annual Healthcare Conference in Boston, MA on Monday, March 6, 2017 at 1:20 p.m. ET (18:20 GMT).
Advertisement
A live audio webcast will be available on the Presentations and Webcasts section of Shire's Investor website at http://investors.shire.com/presentations-and-webcasts/. Subsequently, a replay of the webcast will be available on this same website for approximately 90 days.
NOTES TO EDITORS
About Shire
Shire is the leading global biotechnology company focused on serving people with rare diseases and other highly specialized conditions. We strive to develop best-in-class products, many of which are available in more than 100 countries, across core therapeutic areas including Hematology, Immunology, Neuroscience, Ophthalmics, Lysosomal Storage Disorders, Gastrointestinal / Internal Medicine / Endocrine and Hereditary Angioedema; and a growing franchise in Oncology.
Our employees come to work every day with a shared mission: to develop and deliver breakthrough therapies for the hundreds of millions of people in the world affected by rare diseases and other high-need conditions, and who lack effective therapies to live their lives to the fullest.
http://www.shire.com
For further information please contact: Investor Relations Ian Karp [email protected] +1-781-482-9018
Robert Coates [email protected] +44-1256-894874
SOURCE Shire plc
